AZD2171 (cediranib), a pan-VEGF receptor tyrosine kinase inhibitor, normalizes the structure and function of the tumor vasculature, alleviating edema and increasing tumor perfusion, which is associated with prolonged PFS and OS in recurrent glioblastoma patients 126. This evidence concerns the gene VEGFA and glioblastoma.